Table 1.
Baseline characteristics
| N | % | |
|---|---|---|
| Age, median (range), y | 57 (20-70) | |
| Patient sex | ||
| M | 20 | 60.6 |
| F | 13 | 39.4 |
| Donor sex | ||
| M | 21 | 63.6 |
| F | 12 | 36.4 |
| Patient-donor sex | ||
| FF | 3 | 9.1 |
| FM | 10 | 30.3 |
| MF | 9 | 27.3 |
| MM | 11 | 33.3 |
| Disease | ||
| AML | 25 | 75.8 |
| MDS (RAEB) | 8 | 24.2 |
| Active disease at HSCT (BM ≥5% blasts) | 16 | 48.5 |
| Donor-HLA match (A, B, C, DRB1, DQB1) | ||
| 10/10 related | 14 | 42.4 |
| 10/10 unrelated | 10 | 30.3 |
| 9/10 unrelated | 9 | 27.3 |
| Cell source | ||
| BM | 1 | 3 |
| PBSC | 32 | 97 |
| Conditioning intensity* | ||
| MAC | 12 | 36.4 |
| RIC | 21 | 63.6 |
| GVHD prophylaxis | ||
| Tac/MTX | 16 | 48.5 |
| Tac/Sir | 5 | 15.2 |
| Tac/Sir/MTX | 12 | 36.4 |
| Disease Risk Index | ||
| Low | 2 | 6.1 |
| Intermediate | 11 | 33.3 |
| High | 18 | 54.6 |
| Very high | 2 | 6.06 |
| Patient-donor CMV serology | ||
| Any positive | 23 | 69.7 |
BM, bone marrow; CMV, cytomegalovirus; F, female; M, male; MAC, myeloablative conditioning; MTX, methotrexate; PBSC, peripheral blood stem cell; RAEB, refractory anemia with excess blasts; Sir, sirolimus; Tac, tacrolimus.
*
RIC regimens included busulfan/fludarabine (20) and fludarabine /melphalan (1). Myeloablative regimens included cyclophosphamide/1200 cGy total body irradiation (11) and busulfan/cyclophosphamide (1).